Clinical trials
Toripalimab clinical trials
Below are recruiting toripalimab clinical trials, each written for real people, not researchers. We’re tracking 174 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06437977RecruitingPhase 3
Pre-surgery treatment with radiation, immunotherapy, and chemo for stage II-III NSCLC
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
ShanghaiAges 18–75 - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Little Rock, ArkansasAges 12 years+ - NCT06547203RecruitingPhase 2
Cetuximab, irinotecan, and toripalimab for right-sided colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and toripalimab) for people with advanced right-sided colon cancer that does not have certain gene mutations. It's for those whose cancer has gotten worse after standard treatments.
Guangzhou, GuangdongAges 18–80 - NCT06592326RecruitingPhase 3
Study of 9MW2821 with toripalimab vs chemo for advanced bladder cancer
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06611813RecruitingPhase 2
Chemo plus immunotherapy for HR+/HER2- breast cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
HangzhouAges 18–75 - NCT06612632RecruitingPhase 1/Phase 2
Retrying Immunotherapy for Solid Tumors After First Trial
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
BeijingAges 18 years+ - NCT06623136RecruitingPhase 2
Testing a new combo for advanced lung cancer
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Beijing, Beijing MunicipalityAges 18–75 - NCT06642545RecruitingPhase 2
New targeted drug combo for HER2-low breast cancer
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06657144RecruitingPhase 1
Study of CHS-114 and toripalimab for advanced solid tumors
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
Tucson, ArizonaAges 18 years+ - NCT06682195RecruitingPhase 2
Chemo plus toripalimab before surgery for TNBC
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
Nanchang, JiangxiAges 18–70 - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06712888RecruitingPhase 3
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy toripalimab to standard chemotherapy improves outcomes for people with locally advanced nasopharyngeal cancer that has not spread to other parts of the body. It compares toripalimab to a placebo while everyone receives chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT06843889RecruitingPhase 2
Toripalimab with chemoradiation before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
Guangzhou, Baiyun DistrictAges 18–75 - NCT06851247RecruitingPhase 2
Chemoradiation plus toripalimab for advanced nasopharyngeal cancer
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Guangzhou, GuangdongAges 18–65 - NCT06852287RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct and gallbladder cancer
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
Tianjin, TiaAges 18 years+ - NCT06903858RecruitingPhase 2
Toripalimab plus celecoxib for dMMR/MSI-H colorectal cancer
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06914440RecruitingPhase 2
Radiation and immunotherapy before surgery for HR+/HER2- breast cancer
This trial tests giving a short course of radiation (SBRT), then a chemo drug (Nab-Paclitaxel) with an immunotherapy drug (Toripalimab) before surgery for women with a type of breast cancer called HR+/HER2-. The goal is to see if this combination can shrink tumors more effectively before removal.
Xi'an, Shannxi ProvinceAges 18–75 - NCT06940180RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for sinus cancer
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
Boston, MassachusettsAges 18 years+ - NCT06965231RecruitingPhase 2
Perioperative Toripalimab and Endostatin for Stage II Melanoma
This trial tests a combination of two drugs, toripalimab (an immunotherapy) and endostatin (which targets blood vessels), given before and after surgery for stage II melanoma. The goal is to see if this combination helps prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06977893RecruitingPhase 3
Chemo and immunotherapy for HR+ breast cancer before surgery
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
HangzhouAges 18–75 - NCT06991790Recruiting
Sacituzumab Govitecan and Toripalimab for First-Line Advanced Triple-Negative Breast Cancer
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
BeijingAges 18–75
Hear when a new Toripalimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for toripalimab?
- Yes. Clin2 currently lists 174 recruiting toripalimab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a toripalimab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a toripalimab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.